Clinuvel Pharmaceuticals Ltd (CLVLF) SEC filings

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

SEC filings

16 of Clinuvel Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Annual report	20-F	Jun 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	6-K	Oct 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	6-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	6-K	Oct 7, 2026	Oct 7, 2026	SEC EDGAR
Current report	6-K	Oct 2, 2026	Oct 2, 2026	SEC EDGAR
Current report	6-K	Oct 1, 2026	Oct 1, 2026	SEC EDGAR
Current report	6-K	Sep 8, 2026	Sep 9, 2026	SEC EDGAR
Current report	6-K	Aug 27, 2026	Aug 27, 2026	SEC EDGAR
Current report	6-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Current report	6-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	6-K	Jul 30, 2026	Jul 30, 2026	SEC EDGAR
Current report	6-K	Jul 28, 2026	Jul 28, 2026	SEC EDGAR
Current report	6-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 21, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 21, 2026	Jul 22, 2026	SEC EDGAR

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLVLF.

Revenue growth5.2% · median 17.8%

Gross margin82.9% · median 69.2%

Operating margin43.4% · median -14.2%

Net margin36.0% · median 23.5%

Advertisement
300 × 250

See a number that looks wrong?